ATE348183T1 - Zusammensetzungen und verfahren zur intraductalen gentherapie - Google Patents

Zusammensetzungen und verfahren zur intraductalen gentherapie

Info

Publication number
ATE348183T1
ATE348183T1 AT00914435T AT00914435T ATE348183T1 AT E348183 T1 ATE348183 T1 AT E348183T1 AT 00914435 T AT00914435 T AT 00914435T AT 00914435 T AT00914435 T AT 00914435T AT E348183 T1 ATE348183 T1 AT E348183T1
Authority
AT
Austria
Prior art keywords
methods
ductal
cell
intraductal
compositions
Prior art date
Application number
AT00914435T
Other languages
English (en)
Inventor
Sanford H Barsky
Mary L Alpaugh
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE348183T1 publication Critical patent/ATE348183T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT00914435T 1999-01-20 2000-01-20 Zusammensetzungen und verfahren zur intraductalen gentherapie ATE348183T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11647099P 1999-01-20 1999-01-20

Publications (1)

Publication Number Publication Date
ATE348183T1 true ATE348183T1 (de) 2007-01-15

Family

ID=22367379

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00914435T ATE348183T1 (de) 1999-01-20 2000-01-20 Zusammensetzungen und verfahren zur intraductalen gentherapie

Country Status (9)

Country Link
US (1) US6514695B1 (de)
EP (1) EP1147208B1 (de)
AT (1) ATE348183T1 (de)
AU (1) AU777130B2 (de)
CA (1) CA2356960C (de)
DE (1) DE60032333T2 (de)
ES (1) ES2278596T3 (de)
IL (2) IL143988A0 (de)
WO (1) WO2000042972A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE341345T1 (de) * 1999-06-11 2006-10-15 Cytyc Corp Flüssige gelformulierung zum detektieren von milchkanälen in der brust vor einer chirurgischen ablation des brustgewebes
RU2290933C1 (ru) * 2005-04-11 2007-01-10 Ростовский научно-исследовательский онкологический институт МЗ РФ Способ лечения рака
US11298113B2 (en) 2008-10-01 2022-04-12 Covidien Lp Device for needle biopsy with integrated needle protection
US9186128B2 (en) * 2008-10-01 2015-11-17 Covidien Lp Needle biopsy device
US9332973B2 (en) 2008-10-01 2016-05-10 Covidien Lp Needle biopsy device with exchangeable needle and integrated needle protection
US9782565B2 (en) 2008-10-01 2017-10-10 Covidien Lp Endoscopic ultrasound-guided biliary access system
US8968210B2 (en) 2008-10-01 2015-03-03 Covidien LLP Device for needle biopsy with integrated needle protection

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763415A (en) * 1995-08-03 1998-06-09 John Hopkins University School Of Medicine Destruction of the epithelium of an exocrine gland in the prophylactic and therapeutic treatment of cancer

Also Published As

Publication number Publication date
EP1147208A4 (de) 2002-10-02
EP1147208A2 (de) 2001-10-24
WO2000042972A3 (en) 2000-09-28
CA2356960A1 (en) 2000-07-27
IL143988A (en) 2009-11-18
AU777130B2 (en) 2004-10-07
US6514695B1 (en) 2003-02-04
DE60032333T2 (de) 2007-06-21
IL143988A0 (en) 2002-04-21
CA2356960C (en) 2009-10-06
DE60032333D1 (de) 2007-01-25
WO2000042972A2 (en) 2000-07-27
AU3582700A (en) 2000-08-07
ES2278596T3 (es) 2007-08-16
EP1147208B1 (de) 2006-12-13

Similar Documents

Publication Publication Date Title
TNSN05300A1 (en) Treatment with anti-vegf antibodies
WO2003004989A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
ATE413180T1 (de) Methylation-modulierende verbingungen zur intraduktalen behandlung von brustkrebs
SI1472541T1 (sl) Prikazovalni agensi in postopek prikazovanja naaladase ali psma
IL140700A0 (en) Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
BR0209646A (pt) genes expressos em cáncer de mama como alvos de prognósticos e terapêuticos
PH12015501744B1 (en) Therapeutic and diagnostic target for cancer comprising dll3 binding reagents
WO2003087831A3 (en) Proteins involved in breast cancer
WO2003000012A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer
EA200800268A1 (ru) КОМБИНИРОВАННАЯ ТЕРАПИЯ АНТИТЕЛОМ ПРОТИВ CTLA-4 И СОДЕРЖАЩИМ CpG-МОТИВ СИНТЕТИЧЕСКИМ ОЛИГОДЕЗОКСИНУКЛЕОТИДОМ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛИ
EP1844077A4 (de) Dr5-antikörper und deren verwendung
WO2004106495A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2000055629A3 (en) Methods of diagnosing and treating breast cancer
ATE526037T1 (de) Verfahren zum abtöten von tumorzellen mittels targeting von auf apoptotischen tumorzellen exponierten internen antigenen
BR9807418A (pt) Terapia de gene supressor de tumor combinado e quimioterapia no tratamento de neoplasmas
BR9808509A (pt) Composições e métodos para o tratamento e diagnóstico do câncer de mama
AU3392901A (en) Proteins
WO1999064576A3 (en) Human genes differentially expressed in colon cancer
ATE318328T1 (de) Diagnostika und therapeutika für osteoporose
DE60032333D1 (de) Zusammensetzungen und verfahren zur intraductalen gentherapie
WO2001071357A3 (en) Diagnosis and treatment of breast cancer
MXPA05007940A (es) Composiciones y metodos para el tratamiento del cancer usando igsf9 y liv-1.
MX2025013877A (es) Constructos anti-met basados en anticuerpos silenciados para el tratamiento de tumores y metastasis
EP1470239A4 (de) Psoriasin-ausdruck durch brustepithelzellen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties